DGX at a glance
Quest Diagnostics (DGX, SEC CIK 1022079) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 23, 2026, an 8-K current report on October 22, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Quest Diagnostics (DGX) reported revenue of $11.0 billion (up 11.8% from FY2024) and net income of $992.0 million. Diluted EPS was $8.75.
- As of September 30, 2026, 42 institutional investment managers tracked by SignalX reported holding Quest Diagnostics (DGX) shares worth $12.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Deppe Michael J on November 13, 2026 of 5,515 shares at $260.17 per share.
- In the last 90 days, DGX insiders reported 0 open-market purchases ($0) and 17 open-market sales ($19.8M) on Form 4, a net sale of $19.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $11.0B
- +11.8% vs prior year
- Insiders · 90 days
- 0 buys · 17 sells
- Net −$19.8M
- 13F holders
- 42 funds
- $12.0B · −2 vs prior quarter
- Latest 8-K
- Oct 22, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Revenue $11.0B in FY2025; no explicit YoY dollar comparison provided in the MD&A text
- Advanced Diagnostics segment: oncology, cardiometabolic, brain health, autoimmune, women's health/genetics, exceeded $1B revenue on double-digit growth
- Hospital channel: reference testing ~$1.2B; Collaborative Lab Solutions ~$800M in 2025
- Capital return: quarterly dividend raised ~7.5% to $0.86/share; ~$8.1B returned via buybacks since 2012
- Key risks: PAMA reimbursement reform pending, Project Nova IT modernization through 2031–2032, and evolving AI/regulatory landscape
Risk Factors
- PAMA reimbursement reform risk: Congress introduced 2025 Results Act to fix structural flaws; prior 2018-2020 cuts exceeded original 10-year savings projections
- Debt load $5.7B outstanding as of Dec 31, 2025 with restrictive covenants limiting operational flexibility
- IT modernization via multi-year Project Nova, partnered with Epic; system failure could disrupt billing and customer service operations
- AI-enabled point-of-care and home testing competitors threatening volume; hospitals internalizing advanced testing without commercial labs
- Tariffs and trade policy uncertainty raising supply chain costs for testing equipment and materials across international operations
Business Overview
- Largest national lab services provider: ~$11.0B net revenue in 2025, serving ~⅓ of U.S. adult population annually and processing 244 million test requisitions
- Advanced Diagnostics™ five-franchise segment (oncology, cardiometabolic, brain health, autoimmune, women's health) surpassed $1B revenue on double-digit growth
- Haystack Oncology MRD ctDNA test received FDA Breakthrough Device Designation in 2025 for early-stage colorectal cancer, with clinical trials launched at Mass General Brigham and Rutgers Cancer Institute
- Project Nova launched Feb 2025: multi-year Epic-powered "Order to Cash" modernization targeting completion 2031–2032; Google Cloud generative AI collaboration also announced in 2025
- LifeLabs acquisition (2024) added ~6,800 employees and ~23 million Canadian test requisitions in first full year, bringing global headcount to nearly 57,000
AI summary of the DGX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $3,097M, up 10.0% YoY from $2,816M, driven by DIS revenue growth of 10.2%
- Operating margin 15.5% vs 13.7% YoY, net income $312M vs $245M
- Best performer DIS: $3,035M revenue, up 10.2%; DS revenue $62M vs $61M
- Operating cash flow $611M vs $563M; capital expenditures $166M vs $144M
- Cash $797M vs $420M at December 31, 2025; reimbursement pressures and higher compensation costs remained headwinds
Risk Factors
- No material changes to risk factors reported from December 31, 2025 Form 10-K
- Carried-forward risks remain governed by the 2025 Annual Report’s risk-factor disclosures
AI summary of the DGX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter 2026 results for period ended September 30, 2026
- Press release issued October 22, 2026
Item EX-99.1: Item EX-99.1
- Q3 revenue $3.097B, up 10.0%, with requisition volume up 14.5% offset by revenue per requisition down 4.2%
- Reported diluted EPS $2.78, up 28.7%; adjusted EPS $3.00, up 15.4%, signaling strong operating leverage
Item 8.01: Other Events
- Unauthorized access to Quanum LSM, a client platform for test orders and patient results, identified October 21, 2026
- Certain patient records accessed, creating potential privacy, legal, regulatory and remediation exposure
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Catherine Doherty retirement planned for July 2027, creating a future senior leadership transition
- Executive Vice President role effective November 1, 2026, retaining oversight of health systems, Corewell Health joint venture and Project Nova
AI summaries of DGX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DGX
Don't miss the next DGX filing
- Alerts as it files. A push when DGX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DGX, by share count.
- Ask anything. An AI agent that reads every DGX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Deppe Michael J | Sell | Nov 13, 2026 | 5,515 | $260.17 |
| Deppe Michael J | M | Nov 13, 2026 | 5,515 | $103.57 |
| Deppe Michael J | M | Nov 13, 2026 | 6,261 | $95.80 |
| Deppe Michael J | M | Nov 13, 2026 | 5,515 | $103.57 |
| Deppe Michael J | Sell | Nov 13, 2026 | 6,261 | $260.17 |
| Deppe Michael J | M | Nov 13, 2026 | 6,261 | $95.80 |
| Plewman Patrick | M | Nov 9, 2026 | 6,793 | $127.81 |
| Plewman Patrick | Sell | Nov 9, 2026 | 6,793 | $257.34 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $9.9B | $11.0B |
| Operating Income | - | $1.3B | $1.6B |
| Net Income | $854.0M | $871.0M | $992.0M |
| Op. Margin | - | 13.6% | 14.1% |
| Net Margin | - | 8.8% | 9.0% |
| Balance Sheet | |||
| Total Assets | - | $16.2B | $16.2B |
| Equity | $6.3B | $6.8B | $7.2B |
| ROE | 13.5% | 12.9% | 13.8% |
| Per Share | |||
| EPS | $7.49 | $7.69 | $8.75 |
| Cash Flow | |||
| Operating CF | - | $1.3B | $1.9B |
| CapEx | $408.0M | $425.0M | $527.0M |
Source: XBRL data in Quest Diagnostics (DGX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DGX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 42 | $12.03B |
| Q2 2026 | 44 | $11.35B |
| Q1 2026 | 43 | $10.72B |
| Q4 2025 | 40 | $9.99B |
| Q3 2025 | 41 | $11.76B |
| Q2 2025 | 40 | $10.34B |
| Q1 2025 | 39 | $6.38B |
| Q4 2024 | 33 | $4.66B |
- Invesco Ltd+357.5K (+26%)
- Citadel Advisors LLC+298.4K (+224%)
- Goldman Sachs Group+275.2K (+28%)
- Millennium Management+106.1K (+928%)
- State Street Corp+41.0K (+1%)
- JPMorgan Chase & Co−632.4K (-18%)
- T. Rowe Price Group−424.0K (-8%)
- Bank of America Corp−208.7K (-11%)
- Citigroup−127.0K (-40%)
- Franklin Resources−80.4K (-66%)
- Two Sigma Investments+59.6K
- FMR LLC (Fidelity)−1.40M
- Marex Group plc−1.8K
- PARK NATIONAL CORP /OH/−399
Source: 13F-HR filings on SEC EDGAR (aggregated from 322 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DGX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Oct 28, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 10-Q | Oct 23, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 23, 2026 | - | - | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
DGX SEC filings: frequently asked questions
Are DGX insiders buying or selling?
In the last 90 days, Quest Diagnostics (DGX) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $19.8 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DGX stock?
As of September 30, 2026, the largest Quest Diagnostics (DGX) holders among the 13F filers tracked by SignalX were BlackRock ($2.2 billion), Vanguard Capital Management LLC ($1.7 billion), Vanguard Portfolio Management LLC ($1.4 billion), State Street Corp ($1.3 billion), T. Rowe Price Group ($1.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DGX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Quest Diagnostics (DGX) reported revenue of $11.0 billion (up 11.8% from FY2024) and net income of $992.0 million. Diluted EPS was $8.75. The figures come from the XBRL data in the 10-K.
What are the main risks in DGX's latest 10-K?
In the 10-K filed February 26, 2026, Quest Diagnostics (DGX) flagged: PAMA reimbursement reform risk: Congress introduced 2025 Results Act to fix structural flaws; prior 2018-2020 cuts exceeded original 10-year savings projections. Debt load $5.7B outstanding as of Dec 31, 2025 with restrictive covenants limiting operational flexibility. (AI summary of the Risk Factors section.)
What did DGX report in its latest 8-K?
Quest Diagnostics (DGX) filed an 8-K on October 22, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter 2026 results for period ended September 30, 2026.
What are the latest DGX SEC filings?
Quest Diagnostics (DGX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 23, 2026, an 8-K current report on October 22, 2026 and a Form 4 insider filing on November 16, 2026.
What is DGX's SEC CIK number?
Quest Diagnostics (DGX)'s SEC Central Index Key (CIK) is 1022079. EDGAR lists every DGX filing under that number.
Ask anything about DGX
The research agent reads DGX's filings, financials, insider trades and 13F holders, then answers with sources.